Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Venereologie)
Source: Annales de Dermatologie et de Venereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Venereologie)
Source: Annales de Dermatologie et de Venereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Venereologie)
Source: Annales de Dermatologie et de Venereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Occurrence of O'Brien-type annular elastolytic giant cell granuloma during pravastatin treatment illustrating statin-induced photosensitivity
Ann Dermatol Venereol. 2023 Apr 24:S0151-9638(23)00029-7. doi: 10.1016/j.annder.2023.03.002. Online ahead of print.NO ABSTRACTPMID:37100679 | DOI:10.1016/j.annder.2023.03.002 (Source: Annales de Dermatologie et de Venereologie)
Source: Annales de Dermatologie et de Venereologie - April 26, 2023 Category: Dermatology Authors: C Breton L Gusdorf A Durlach M Viguier Source Type: research
Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers
In conclusion, this study suggests that OATP1B substrate drugs as well as CYP3A4 substrates may safely be used without dose adjustment in patients treated with bulevirtide. However, in patients using high statin doses and where concomitant factors potentially further increase statin exposure, caution may be required when using bulevirtide. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - April 6, 2023 Category: Drugs & Pharmacology Source Type: research
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study
ConclusionsPersistent statin use can reduce cardiovascular mortality in patients with T2DM; in particular, the higher is the cDDD-year of statin, the lower is the cardiovascular mortality. The optimal statin dose daily was 0.86 DDD. The priority of protective effects on mortality are pitavastatin, rosuvastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, and lovastatin for the statin users compared with non-statin users. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 3, 2023 Category: Drugs & Pharmacology Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Atherosclerosis)
Source: Atherosclerosis - March 31, 2023 Category: Cardiology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Atherosclerosis)
Source: Atherosclerosis - March 31, 2023 Category: Cardiology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
Effects of xuezhikang versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia: study protocol for a multicenter randomized controlled trial
CONCLUSION: This study will evaluate the effect of a 6-week treatment with xuezhikang compared with pravastatin on fasting and postprandial TG levels and other blood lipid parameters in patients with T2DM and dyslipidemia without atherosclerotic cardiovascular disease (ASCVD). The results will provide more information on optimizing the lipid control of patients with diabetes in the primary prevention of ASCVD.PMID:36998136 | DOI:10.2174/1570161121666230328110215 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Authors: Jin Xu Liyuan Zhu Yingying Xie Miao Zhang Zixi Xiao Rongkai Su Tie Wen Ling Liu Source Type: research
